Closing prices for 09 October 2026
Next earnings report: 27 October 2026 · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
IQVIA Holdings, Inc. trades on NYSE under the ticker IQV. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks IQV has traded between 154.50 $ and 277.40 $. As of 09 October 2026 the price stood 85.74 % of the way from the 52-week low to the high.
Over one year IQV shares rose 29.55 %; over six months they rose 55.30 %. Volatility over 90 days is 38.26 %. Dividends are not included: this is price change only, as of 09 October 2026.
IQV trades at a price-to-earnings ratio of 30.9, above the sector median of 24.8. Price to sales is 2.6, below the sector median of 3.9. Price to book is 6.9, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 257.73 | 263.51 | 258.71 | 259.88 | 972,314 |
| 08 October 2026 | 256.01 | 259.95 | 252.56 | 258.88 | 988,400 |
| 07 October 2026 | 261.41 | 261.41 | 255.05 | 258.11 | 1M |
| 06 October 2026 | 269.43 | 274.28 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
IQVIA runs clinical trials for drug companies and sells pharmaceutical market data.
For a drug developer it is cheaper to hire a contractor than to maintain its own network of research sites: a trial requires hundreds of locations across countries, physician coordination and regulatory reporting. The company does this professionally and secures contracts years ahead.
The second part is data: prescription and drug sales information bought by the same pharmaceutical companies for planning. That is subscription revenue at high margins. Risks: reduced research budgets, especially at biotech start-ups dependent on raising capital. The trial backlog is the leading indicator, and it turns months before revenue does. The company pays no dividend.
Address:2400 ELLIS ROAD, DURHAM, NC, 27703, US
IQVIA Holdings, Inc. reported revenue of 16.6B $ and net income of 1.4B $ over the last four quarters. Net margin is 8.33 %. Revenue changed by +7.32 % year over year. Earnings per share are 8.05 $. Market capitalisation is 42.8B $.
IQV has a return on equity of 22.26 %, above the sector median of −41.68 %. Return on assets is 4.67 %, above the sector median of −32.11 %. Operating margin is 13.23 %, above the sector median of −26.84 %.
| 146M |
| BIAFbioAffinity Technologies, Inc. | 4.69 | −16.84 % | 67M |
| ABSIAbsci Corporation | 10.14 | +13.37 % | 39M |
| OABIOmniAb, Inc. | 4.79 | +2.79 % | 7M |
| NRCNRC Health | 20.33 | −0.44 % | 3M |
| 259.79 |
| 259.98 |
| 1M |
| 05 October 2026 | 258.51 | 266.91 | 258.51 | 266.09 | 2M |
| 02 October 2026 | 260.70 | 261.98 | 257.07 | 258.21 | 1M |
| 01 October 2026 | 268.02 | 268.88 | 259.31 | 260.72 | 1M |
| 30 September 2026 | 269.96 | 273.16 | 267.61 | 268.85 | 2M |
| 29 September 2026 | 271.46 | 273.50 | 266.43 | 268.99 | 1M |
| 28 September 2026 | 266.52 | 272.75 | 265.97 | 270.97 | 2M |
| 25 September 2026 | 274.90 | 274.90 | 269.43 | 270.37 | 1M |
| 24 September 2026 | 266.46 | 277.13 | 266.46 | 275.02 | 2M |
| 23 September 2026 | 270.66 | 277.40 | 267.42 | 267.86 | 1M |
| 22 September 2026 | 270.25 | 272.44 | 267.26 | 270.09 | 950,700 |
| 21 September 2026 | 266.76 | 270.86 | 265.25 | 269.88 | 2M |
| 18 September 2026 | 269.45 | 269.45 | 264.88 | 266.42 | 6M |
| 17 September 2026 | 273.15 | 273.88 | 267.92 | 269.44 | 2M |
| 16 September 2026 | 270.89 | 273.56 | 268.57 | 268.82 | 2M |
| 15 September 2026 | 263.17 | 272.35 | 262.95 | 269.67 | 1M |
| 14 September 2026 | 265.77 | 267.95 | 262.56 | 265.67 | 1M |